Hopeful signs for Elan

ATHLONE-BASED pharmaceutical company Elan has been assigned a hold recommendation

Hopeful signs for Elan

Analyst Ronan Wallace said prices agreed for disposals to date have generally been in excess of what would have been expected.

"Allied to good prices has been positive comments from the company's Chairman that Elan should reach its target ahead of schedule and that proceeds are likely to exceed original estimates. While this bodes well for achieving its short-to-medium term goals, there still remains significant risk associated with the stock," he said.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited